578 Index. Eplerenone, 7, 29, 119, 120, 126, 275, 276,

Transcription

1 Index A AC. See Adenylate cyclase (AC) ACEI. See Angiotensin converting enzyme inhibitors (ACEI) Adenosine, 179, 180, , 191, Adenosine A1 receptor, , 186, Adenylate cyclase (AC), 180, 181, 185, 186, 192, 193, 251 Adrenergic receptor, 207, 472 AF. See Atrial fibrillation (AF) Allogeneic, , 338, 339, Anemia, 22, 24, 29, 37 39, 47, 49, 52, 503 Angiogenesis, 348, 357, 359, , 380, 400, 408, 409, 414 Angiotensin converting enzyme inhibitors (ACEI), 6 9, 19, 26, 29, 55, 70, 81, 83, 86, 88, 91, 93, , 123, 124, 126, 127, 136, 137, 140, 141, , 154, 157, 158, 169, 171, 173, 193, 275, 288, , 296, 297, 309, 401, 467, 472, 482, 484, 526, , , 556 Angiotensin receptor blockers (ARB), 5 7, 9, 19, 26, 29, 81, 83, 111, , , 135, 137, 141, 144, 146, 149, 154, 157, 233, 275, 288, , 296, 297, 467, 472, 482, 484, 526, 539, 541, 544, 546, 556 Animal models of human disease, 234, 285, 399, , 496 ARB. See Angiotensin receptor blockers (ARB) Arginine vasopressin (AVP), 93, , 316, 317, , 324, 325 Atrial fibrillation (AF), 3, 8, 20, 22, 23, 26, 40, 54, 94, 122, 125, 148, 155, 158, 170, 173, 239, 291, 292, 472, 473, AVP. See Arginine vasopressin (AVP) B Basic science research, 399, 407 Biomarkers, 45, 69, 70, 72, 79 97, 139, 142, 143, 152, 216, 239, 438, 439, 480, 518, Bleeding, 516, 517, 520, , 529, 530 C Calcium, 111, 120, 180, 185, 190, , 198, 212, 213, 228, , 257, , 279, 284, 357, 402, 449, , 455, 456, , 542, 544, 545, 547, 548, 552, 563 Cardiac hypertrophy, 216, 233, 237, 255, 256, 276, , 285, , 383, , 438, 454, 501 Cardiac myosin activation, Cardiac output (CO), 3, 111, 172, 191, 196, 228, 231, 232, 238, 256, 259, 274, 313, 317, 324, 325, 467, , 482, 486, 496 Cardiac remodeling, 83, 89, 209, 216, 217, 232, 255, 274, 276, 310, , 430, 433, 434, 438, 454 Cardiovascular (CV), 2, 3, 5, 7 10, 25, 45, 46, 48, 54, 55, 69 71, 73, 74, 80, 86, 88, 90, 92, 93, 95, 97, 111, 117, 118, 121, 127, , 140, 146, , 154, 155, 158, 169, , , 216, 217, , 237, , 262, 274, 276, 278, 283, , , , 340, 347, 362, , , , 407, 409, 410, 424, 426, 427, 432, 459, 473, 486, 492, 498, , , 528, 530, 545, 567, 569 Cardiovascular mortality, 43, 45, 48, 55, 69, 70, 74, 86, 122, 168, 381, 383, 504, 506, 569 # Springer International Publishing AG 2017 J. Bauersachs et al. (eds.), Heart Failure, Handbook of Experimental Pharmacology 243, DOI /

2 578 Index Catecholamines, 55, 87, 115, 180, 193, 198, , 214, 376, 405, 542 cgmp. See Cyclic guanosine monophosphate (cgmp) Chronic heart failure, 21, 23, 36, 37, 48, 68 70, 76, 77, 112, 124, 153, 170, 173, 207, 216, 227, 250, 348, 416, 448, 486, 503 Chronic kidney disease (CKD), 3, 38, 51, 52, 91, 156, 239, , 283, 284, 292, 293, 296, 298, 539, , 554, 556, 563 Cinaciguat, Circular RNA, 425 CKD. See Chronic kidney disease (CKD) CO. See Cardiac output (CO) Cognitive dysfunction, 37, Comorbidities, 2, 8, 20 25, 35 58, 82, 86, 87, 91, 92, 94, 97, 127, 154, , 194, 227, , 241, 260, 274, 281, 522, 523, 565, 566, 569 Copeptin, 85, 93, , 320, 321 CV. See Cardiovascular (CV) Cyclic guanosine monophosphate (cgmp), 8, 9, 138, , 211, 212, 214, 215, , , Cyclic nucleotides, 228, , 262, 263 D Deoxy adenosine triphosphate (datp), , , 461, 462 Diabetes mellitus (DM), 2, 23, 26, 37, 42 46, 51, 115, 118, 153, 168, 171, 184, 185, 227, 231, 235, 239, 256, 274, 293, 296, 297, 542, 543, 549 Diagnosis, 3, 16, 17, 20, 37, 41, 42, 54, 80, 81, 85, 94, 139, 153, 438, 518, , 565 DM. See Diabetes mellitus (DM) Drug safety, 77, 118, 122, 145, , 158, 159, , 189, 315, 524, 555 Drug-therapy, 5, 8, 43, 46, 69, 88, 89, 92, 217, 315, 473, 519, 520, 524 E Energetics, 182, 186, 188, , 194, 199, 399, 401, 403, 453, 454, 471, , , 499, 504 Epidemiology, 15 30, 37 39, 41, 42, 47, 51, 53, 58, 539 Eplerenone, 7, 29, 119, 120, 126, 275, 276, F Ferric carboxymaltose (FCM), 48, 49, 504, 565, 568 Ferritin, 47, 49, 92, 562, 564, 565, Finerenone, 7, 275, 282, , Frizzled, 372, 373, 377, 379, 384 Funny channel, 111, 121 G Gene therapy, 38, , Gene therapy vectors, Growth factors/cytokines, 92, 231, Guidelines, 2 8, 10, 20 22, 25, 43, 46, , 168, 173, 293, 297, 435, 472, 500, 546, 556, 565, 569 H Heart failure (HF), 2 3, 15 30, 35 58, 70, 71, 73 74, 79 97, , , 170, , , 207, , 250, , , , , , , , , , , , , , Heart failure management, 3, 16, 21, 80 82, 97, 146, 171, 292, 405, 569 Heart failure statistics, 2, 473 Heart failure trials, 69, 74 Heart failure with preserved ejection fraction (HFpEF), 3 6, 8 10, 20, 21, 27, 30, 42, 45 47, 52, 68, 81, 93 97, 110, , 136, 146, 147, 157, 159, 173, 187, , 197, 213, 215, 216, 227, , 238, 240, 260, 261, 263, 285, , 356, 357, 432, 502, 506, 567 Heart failure with reduced ejection fraction (HFrEF), 2 10, 20, 21, 30, 38, 42, 44 46, 48, 49, 52, 54, 56, 58, 68, 81 84, 86 97, 110, , , , 136, 137, 142, , 150, 158, 159, 187, , 196, 227, 228, , , 274, 275, , 432, 467, 468, 470, 472, 473, 476, 477, 479, 480, 482, , 503, 546, 556,

3 Index 579 Heart rate, 8 10, 22, 23, 27 29, 44, 46 48, 72, 76, 113, 121, 124, 168, 169, 172, 173, 183, 184, 189, 190, 193, 216, 238, 251, 313, 325, 454, 459, 470, 472, 476, 477, 480, 482, 483, 485, 486, 502, 526 Hematinic deficiencies, 65, Hepcidin, 38, 39, 47, 49, HF. See Heart failure (HF) HFpEF. See Heart failure with preserved ejection fraction (HFpEF) HFrEF. See Heart failure with reduced ejection fraction (HFrEF) Hospitalizations, 2, 3, 6 10, 16 21, 25, 40, 42 46, 48, 55, 68 71, 73 75, 83 85, 89, 90, 92, 94 96, 112, 114, , 125, 127, 136, 140, , 154, 155, 158, , 227, 239, 240, 255, 274, 290, 291, 295, 296, 309, 310, 314, 318, 320, 323, 448, 472, 473, 483, 504, 506, 516, 519, 528, 530, 544, Hyperkalemia, 37, 50, 51, 115, 118, 155, 157, 274, 275, 283, 284, 288, , 296, 297, Hypertrophy, 4, 87, 93, 94, 115, 198, 209, , 232, 233, 235, 237, , 258, , 276, , 285, 289, 291, 356, 360, , 383, 401, 406, 430, , 454, 501, 502, 504 I Inflammation, 22, 37, 38, 41, 47, 49, 52, 85, 86, 88, 95, 96, 113, 137, 196, 215, , 263, 277, 278, 347, 348, 363, 379, 380, 406, 414, 518, Inotropic therapy, 86 Intravenous (iv), 10, 74, 86, 116, 137, 151, 184, 187, 257, 325, 344, , 457, 473, 474, 476, 478, 480, , 499, 504, 544 Intravenous iron, 47 49, 499, 504, Iron deficiency, 37, 38, 47 49, 92, 499, 503, Iron therapy, 47 49, 506, 569 M Mesenchymal stem cells (MSCs), , 385 MI. See Myocardial infarction (MI) Mineralocorticoid receptor antagonists (MRAs), 6 8, 81, 83, 87, 111, , 126, 127, 154, 158, 173, , 309, 467, 472, 482, 484, 539, 541, 543, 544, 546, 556 mirnas, 93, , 435, 438 Mitochondria, 191, 194, , 501, 504, 505 Molecular targets, 384, 401, 404 MRAs. See Mineralocorticoid receptor antagonists (MRAs) MSCs. See Mesenchymal stem cells (MSCs) Myocardial infarction (MI), 2, 7, 44, 88, 112, 114, 115, 117, 118, 127, 144, 149, 155, 159, 186, 187, 232, 237, 253, 258, 263, 280, 281, 285, , 331, 348, 359, 363, 364, 375, , , 397, , , 473, 483, 496, 500, 504, 518, 519, 524, 530, 545 Myocardium, 138, 172, 190, 212, 215, 229, 235, 251, 252, 258, 261, 263, 346, 348, 349, 356, 358, 359, 362, 363, 365, 397, 398, 405, 407, 409, , 433, 449, 450, 457, 459, 496, 499, 504 Myosin activator, 467, 486 N Natriuretic peptides (NP), 7, 9, 82 84, 86, 90, 92, 94 95, 118, 125, , 229, 251, 258, 263, 320, 483, 484, 486 ncrna therapy, 425 Neladenoson, 183, 189 Neprilysin (NEP), 7, 70, 82, 84, 118, , 144, 147, 152, 156 Nitric oxide (NO), 8, 9, 115, 116, 120, 198, , 217, , , 241, 251, 258, 260, 261, 263, 281 Novel oral anticoagulant (NOACs), NP. See Natriuretic peptides (NP) L Long noncoding RNAs, 436 O Omecamtiv mecarbil, 449,

4 580 Index P PARADIGM-HF. See Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Patiromer, 50, 51, 538, 545, 546, , 554, 556 Phosphodiesterases (PDE), 145, 228, , 470 PKA. See Protein kinase A (PKA) PKG. See Protein kinase G (PKG) Prognosis, 3, 40, 46, 51, 52, 58, 70, 83, 86, 88, 91, 233, 309, 311 Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF), 5, 7, 84, 86, 117, 118, 136, , , 544 Protein kinase A (PKA), 181, 208, 210, , 257, 258, 263, 405, 470, 472 Protein kinase G (PKG), 228, 231, 232, 235 R Randomized clinical trials (RCTs), 8, 16, 38, 43, 45 48, 137, 297, 332, 333, 343, 344, 346, 524, 530, 567 RASSi. See Renin-angiotensin-aldosterone system inhibitors (RASSi) RCTs. See Randomized clinical trials (RCTs) Reactive oxygen species (ROS), 185, 191, 193, , 230, 278, 279, 348, 406, 493, , 505, 518 Registries, 3, 16, 21 26, 29, 76 Regulatory, 67 77, 236, 251, 258, 262, 264, 278, 312, 332, 398, 424, 426, 436, 457, 469, 470, 503 Remodeling, 45, 69, 70, 74, 83, 86, 87, 89 91, 97, 115, 138, 158, 182, 188, 192, 194, 207, 209, , 230, 232, 233, 250, 261, 274, 276, , 284, 310, 317, 348, , 397, 398, 403, 405, 430, 433, 434, 438, 454, 472, 485, 486, 496 Renal failure, 40, 197, 233, 274, 484 Renin-angiotensin-aldosterone system inhibitors (RASSi), 539 Ribonucleotide reductase (R1R2), 403, 404, 450, , 461, 462 Riociguat, 233, , 241 ROS. See Reactive oxygen species (ROS) Routes of gene delivery, R1R2. See Ribonucleotide reductase (R1R2) S Sacubitril/valsartan, 5, 7, 84, 117, 118, 121, , 190 Screening, 40 42, 53, 80, 81, 97, 156, 157, 183, 235, 284, 425, 427, , 539, 568 SDB. See Sleep-disordered breathing (SDB) SET. See Systolic ejection time (SET) sgc. See Soluble guanylate cyclase (sgc) sgc activator, 215, sgc stimulator, 9, Sinoatrial node, 8, 168 Sleep apnea, 53, 55, 56 Sleep-disordered breathing (SDB), 37, Sodium polystyrene sulfonate (SPS), , 551 Sodium zirconium cyclosilicate (ZS-9), 50, 51, 546, 547, , 556 Soluble guanylate cyclase (sgc), 9, 211, 215, , 251 Soluble transferrin receptor (stfr), 565 Spironolactone, 7, 9, 29, 50, 51, 87, 95, 96, 119, 127, 275, 276, 280, 282, 283, , 544, 550 SPS. See Sodium polystyrene sulfonate (SPS) Stage C, 81, , 116, 123, 125, 126 Stem cells, , , stfr. See Soluble transferrin receptor (stfr) Stroke, 44, 76, 88, 127, 149, 155, 173, 188, 196, 233, 238, 241, 500, 516, , , 529, 530, 567 Systolic ejection time (SET), 474, T Therapeutic target, 37, 58, 191, 192, 228, 259, 263, 376, 388, 405, 425, 427, 429, 433, 435 Therapy, 3, 5 10, 17, 20, 21, 23, 37 40, 43, 46 53, 55 58, 68, 69, 74, 76, 83 92, 94, 95, 97, 110, , 116, 119, , 136, 137, 139, 140, 148, 150, 154, 155, 158, 168, 173, 183, 185, , 193, 194, 198, 199, , 227, 232, 237, 239, 257, 259, 260, 264, 275, 297, 309, 311, , , 362, 364, 365, 384, 385, , 425, , 439, , 467, 472, 473, , , , 538, 539, , 568, 569 Thrombosis, Transferrin saturation (Tsat), 47, 92, 504, 565,

5 Index 581 Translational medicine, 429, Tsat. See Transferrin saturation (Tsat) W Wnt Signaling, V Vasopressin receptor antagonist (VRA), 310, 313, 315, 316, Vericiguat, 9, 228, 232, VRA. See Vasopressin receptor antagonist (VRA) Z ZS-9. See Sodium zirconium cyclosilicate (ZS-9)